Vol 10, No 1 (2019)
Case report
Published online: 2019-06-19
The coexistence of myeloid and lymphoid malignancies in the same patient — two rare case reports
DOI: 10.5603/Hem.2019.0015
Hematologia 2019;10(1):62-68.
Abstract
The coexistence of myeloid and lymphoid malignancies in the same patient is a rare condition. In this article we describe two case reports of patients who developed these two hematological malignancies. The first patient was 25 years-old male, who developed chronic myeloid leukemia 12 months after Burkitt’s lymphoma treatment. In the second patient, 55 years-old female, plasma cell myeloma and polycythemia vera was diagnosed simultaneously. It is still unclear what mechanisms lead to development of two hematological neoplasms originating from two separate cell lineages of hematopoiesis in one patient. Larger studies to establish pathogenesis, epidemiology, prognosis but primarily diagnosis and treatment methods are required.
Keywords: myeloproliferative neoplasmslymphoid malignanciescoexistence
References
- Dozzo M, Carobolante F, Donisi PM, et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2017; 8: 11–29.
- Grimm KE, O'Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol. 2019; 38: 6–10.
- Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017; 28(suppl_4): iv41–iv51.
- Castella M, Fernández de Larrea C, Martín-Antonio B. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. Int J Mol Sci. 2018; 19(11).
- Nangalia J, Green AR, Nangalia J, et al. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017; 130(23): 2475–2483.
- Garcia-Manero G, Faderl S, O'Brien S, et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003; 98(3): 437–457.
- Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011; 86(12): 1007–1012.
- Marchetti M, Carobbio A, Capitoni E, et al. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Am J Hematol. 2018; 93(5): 698–703.
- Trifa AP, Cucuianu A, Popp RA, et al. Concomitant Myeloproliferative and Lymphoid Neoplasms in Two Patients Positive for JAK2 V617F Mutation. Case Report and Literature Review. Indian J Hematol Blood Transfus. 2014; 30(Suppl 1): 120–123.
- Crescenzi B, Sacchi S, Marasca R, et al. Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. Leukemia. 2002; 16(5): 955–956.
- D'Arena G, Gemei M, Luciano L, et al. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol. 2012; 30(32): e327–e330.
- Henry L, Carillo S, Jourdan E, et al. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol. 2007; 82(6): 500–501.
- Swierczek S, Nausova J, Jelinek J, et al. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol. 2013; 88(2): 157–158.
- Ragupathi L, Najfeld V, Chari A, et al. A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature. Clin Lymphoma Myeloma Leuk. 2013; 13(2): 175–179.
- Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012; 122(11): 3888–3899.
- Tabaczewski P, Nadesan S, Lim HS. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V617F positive essential thrombocytopenia: A common defective stem cell? Leuk Res. 2009; 33(6): 854–855.
- Korkmaz S, Kulakoglu S, Gorkem H, et al. Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature. Ann Saudi Med. 2016; 36(5): 364–366.
- Miranda MB, Lauseker M, Kraus MP, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016; 30(6): 1255–1262.
- Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018; 132(7): 694–706.
- Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998; 29(1-2): 17–26.
- Berndt SI, Camp NJ, Skibola CF, et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016; 7: 10933.
- Krahling T, Balassa K, Kiss KP, et al. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100. Cancer Epidemiol Biomarkers Prev. 2016; 25(1): 98–104.
- Park SL, Caberto CP, Lin Yi, et al. Association of cancer susceptibility variants with risk of multiple primary cancers: The population architecture using genomics and epidemiology study. Cancer Epidemiol Biomarkers Prev. 2014; 23(11): 2568–2578.
- Meerkin D, Ashkenazi Y, Gottschalk-Sabag S, et al. Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia. Cancer. 1994; 73(3): 625–628.
- Malhotra J, Kremyanskaya M, Schorr E, et al. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. Clin Lymphoma Myeloma Leuk. 2014; 14(1): 31–36.
- Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009; 27(28): 4760–4766.
- Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007; 21(8): 1827–1828.
- Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004; 22(3): 424–431.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)